Source-grounded facts extracted from Instil Bio, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Instil Bio, Inc. shareholders approved Ratification of RSM US LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-11 meeting.
“Stockholders ratified the selection by the Audit Committee of the Board of RSM US LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Instil Bio, Inc. shareholders approved Election of Class II directors at the 2026-06-11 meeting.
“Stockholders elected the following nominees to serve as Class II directors on the Company’s board of directors (the “Board”) until the Company’s 2029 Annual Meeting of Stockholders and until his successor has been duly elected and qualified.”
Instil Bio, Inc. reported the quarter ended March 31, 2026 results: EPS Net loss per share, basic and diluted was $0.62 for the three months ended March 31, 2026.
“Net loss per share, basic and diluted was $0.62 for the three months ended March 31, 2026, compared to $4.32 for the three months ended March 31, 2025.”
Instil Bio, Inc. engaged RSM US LLP as its auditor.
“(the “Company”) approved the appointment of RSM US LLP (“RSM”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Instil Bio, Inc. dismissed Deloitte & Touche LLP as its auditor.
“(the “Company”) approved the appointment of RSM US LLP (“RSM”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Instil Bio, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss per share, basic and diluted was $1.21 and $10.70 for the fourth quarter and full year ended December 31, 2025,, EPS Net loss per share, basic and diluted was $1.21 and $10.70 for the fourth quarter and full year ended December 31, 2025,.
“On March 27, 2026, Instil Bio, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the fourth quarter and full year ended December 31, 2025”
Instil Bio, Inc. terminated License and Collaboration Agreement with ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (effective 2026-01-05).
“Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil Bio, Inc., and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (“ImmuneOnco”) entered into an agreement terminating, effective January 5, 2026, the License and Collaboration Agreement dated August 1, 2024 between ImmuneOnco and Axion”
Instil Bio, Inc. announced a restructuring with charges of up to $5.5 million affecting Manchester, UK operations (eliminating its remaining UK workforce).
“expected to be substantially complete by the end of 2024. In connection with the Plan, the Company currently estimates that it will incur aggregate restructuring costs of up to $5.5 million, including asset impairment charges of up to $2.2 million, employee termination costs, including severance and other benefits of up to $2.0 million, and contract termination”
Instil Bio, Inc. reported the quarter ended March 31, 2024 results: EPS Net loss per share, basic and diluted were $3.74.
“On May 10, 2024 , Instil Bio, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended March 31, 2024 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.”
Instil Bio, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
“Instil Bio, Inc. (the “Company”) provided a corporate update and announced its financial results for the fourth quarter and full year ended December 31, 2023 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.”
Instil Bio, Inc. announced a restructuring with charges of up to $6.1 million affecting Manchester, UK manufacturing and clinical trial operations (approximately 61%).
“report clinical data from the ITIL-306-202 clinical trial in 2024 . In connection with the Plan, the Company estimates that it will incur aggregate restructuring costs of up to $6.1 million, including employee termination costs, including severance and other benefits, and contract termination costs. The charges that the Company expects to incur in connection with”
Instil Bio, Inc.: Amended certificate to effect 1-for-20 reverse stock split (effective 2023-12-07).
“On December 7, 2023, Instil Bio, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware a certificate of amendment to its amended and restated certificate of incorporation (the “Charter Amendment”) to effect the previously disclosed 1-for-20 reverse stock split of the Company’s common stock (the “Reverse Stock Split”).”
Instil Bio, Inc. reported the quarter ended September 30, 2023 results: net income Net loss $(67,432) (in thousands), EPS Net loss per share, basic and diluted $(0.52).
“On November 13, 2023 , Instil Bio, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended September 30, 2023 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.”
Instil Bio, Inc. reported second quarter 2023 results: net income $0.58 for the six months ended June 30, 2023, EPS $0.14 for the three months ended June 30, 2023.
“Instil Bio, Inc. (the "Company") provided a corporate update and announced its financial results for the quarter ended June 30, 2023 in the press release attached hereto as Exhibit 99.1”
Instil Bio, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-14 meeting.
“Stockholders ratified the selection by the Audit Committee of the board of directors of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2023. The voting results were as follows: Votes For Votes Against Abstentions Broker Non- Votes 116,563,499 461,427 19,878 —”
Instil Bio, Inc. shareholders approved Approval of a series of alternate amendments to the Certificate of Incorporation to effect a reverse stock split at a ratio ranging from one-for-ten to one-for-thirty at the 2023-06-14 meeting.
“Stockholders approved a series of alternate amendments to the Company’s Certificate of Incorporation to effect, at the option of the board of directors, a reverse stock split of the Company’s common stock at a reverse stock split ratio ranging from one-for-ten (1:10) to one-for-thirty (1:30), inclusive, with the effectiveness of one of such amendments and the abandonment of the other amendments, or the abandonment of all amendments, to be determined by the board of directors prior to the date of the 2024 Annual Meeting of Stockholders. The voting results were as follows: Votes For Votes Against Abstentions Broker Non- Votes 116,204,120 819,157 21,527 —”
Instil Bio, Inc. shareholders approved Election of Class II directors at the 2023-06-14 meeting.
“Stockholders elected each of the following nominees to serve as Class II directors on the Company’s board of directors until the Company’s 2026 Annual Meeting of Stockholders and until his successor has been duly elected and qualified. The voting results for such nominees were as follows: Director Name Votes For Votes Withheld Broker Non- Votes George Matcham 96,302,290 566,823 20,175,691 Neil Gibson 85,895,664 10,973,449 20,175,691”
Instil Bio, Inc. reported quarter ended March 31, 2023 results: net income $ (57,068), EPS $ (0.44).
“On May 11, 2023 , Instil Bio, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended March 31, 2023 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.”
Instil Bio, Inc. reported the full year ended December 31, 2022 results: net income Net loss $ (223,177), EPS Net loss per share, basic and diluted $ (1.72).
“Net loss $ (53,844) $ (55,350) $ (223,177) $ (156,794) Net loss per share, basic and diluted $ (0.41) $ (0.43) $ (1.72) $ (1.48)”
Instil Bio, Inc. reported the fourth quarter ended December 31, 2022 results: net income Net loss $ (53,844), EPS Net loss per share, basic and diluted $ (0.41).
“Net loss $ (53,844) $ (55,350) $ (223,177) $ (156,794) Net loss per share, basic and diluted $ (0.41) $ (0.43) $ (1.72) $ (1.48)”
Instil Bio, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“January 24, 2023, Instil Bio, Inc. (the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Select Market. The Company has 180 calendar days, or until July 24, 2023, to regain compliance with the minimum bid price requirement. To regain compliance, th”
Instil Bio, Inc. announced a restructuring with charges of up to $20 million affecting ITIL-168 development program and U.S. workforce (approximately 60%).
“As part of the Plan, the Company’s ITIL-168 development program will be discontinued. In addition, as part of the Plan, the Company will reduce its US workforce by approximately 60%. This workforce reduction is expected to be substantially completed in February 2023. In connection with the Plan, the Company estimates that it will incur aggregate restructuring costs of up to $20 million.”
Timothy Moore departed as Chief Operating Officer at Instil Bio, Inc..
“Timothy Moore, the Company’s Chief Operating Officer, will separate from the Company, effective December 8, 2022.”
Instil Bio, Inc. reported the quarter ended September 30, 2022 results: EPS $ (0.43).
“On November 14, 2022, Instil Bio, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended September 30, 2022 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.”
Timothy L. Moore was appointed as Chief Operating Officer at Instil Bio, Inc..
“On September 6, 2022 (the “Effective Date”), the board of directors (the “Board”) of Instil Bio, Inc. (the “Company”) appointed Timothy L. Moore as Chief Operating Officer of the Company.”
Nimish Shah resigned as Member of the board of directors at Instil Bio, Inc..
“On December 17, 2021, Nimish Shah resigned, with immediate effect, from his role as a member of the board of directors (the “Board”) of Instil Bio, Inc. (the “Company”) and as a member of the Board’s audit committee (the “Audit Committee”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.